[CAS NO. 299-75-2] Treosulfan

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [299-75-2]

Catelog

HY-16503

Brand

MCE

CAS

299-75-2

DESCRIPTION [299-75-2]

Overview

MDL	-
Molecular Weight	278.30
Molecular Formula	C6H14O8S2
SMILES	O[C@H]([C@@H](O)COS(C)(=O)=O)COS(C)(=O)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.

Summary

Treosulfan (NSC 39069) is a bifunctional alkylating agent with activity in ovarian cancer and other solid tumor types.

IC50 & Target

DNA Alkylator ^[1]

In Vitro

Treosulfan is an alkylating agent. Treosulfan inhibits several cancer cell lines, such as Panc-1, Miapaca-2 and Capan-2 cells, with IC ₅₀ s of 3.6 μg/mL, 1.8 μg/mL and 2.1 μg/mL respectively, and shows nearly 100% cytotoxicity on these cell lines at 100 μg/mL. Treosulfan (0.1-100 μg/mL) in combination with LY 188011 exhibits enhanced activity against cancer cells. However, Treosulfan (1, 2.5, 5 μg/ml) combined with 5-FU (0.1, 0.25, 0.5 μg/ml) has antagonistic effect on Panc-1 cells at intermediate and high concentrations, and on Miapaca-2 cells at all doses ^[1] . Treosulfan (800 µg/mL) dramatically reduces erythrocyte forward scatter, increases the percentage of annexin-V-binding cells, [Ca ²⁺ ] _i , and ROS. Removal of extracellular Ca ²⁺ abrogates the effect of Treosulfan on annexin-V-binding ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Treosulfan (1.5 g/kg/day) induces a rapid myeloablation, depletes the splenic B and T cells in mice. Treosulfan (1.5 g/kg/day) causes olny interleukin-2 production in spleen cells for a short time and without obvious significant effect on synthesis of tumor necrosis factor-α and/or IFN-γ in mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00779714	University of Wuerzburg\|Hiege-Stiftung gegen Hautkrebs\|medac GmbH\|DCS Innovative Diagnostik Systeme	Melanoma	October 2008	Phase 3
NCT01079013	Sheba Medical Center	Non Hodgkin Lymphoma\|Hodgkin Lymphoma	March 2010	Phase 2
NCT04965597	Fred Hutchinson Cancer Center\|Blood and Marrow Transplant Clinical Trials Network\|National Cancer Institute (NCI)\|National Marrow Donor Program\|National Heart, Lung, and Blood Institute (NHLBI)	Bone Marrow Failure Syndrome\|Congenital Amegakaryocytic Thrombocytopenia\|Congenital Pure Red Cell Aplasia\|Hereditary Sideroblastic Anemia\|Myeloid Neoplasms With Germline GATA2 Mutation\|Paroxysmal Nocturnal Hemoglobinuria\|Shwachman-Diamond Syndrome	April 19, 2022	Phase 2
NCT00170690	North Eastern German Society of Gynaecological Oncology	Ovarian Cancer	August 2004	Phase 3
NCT02048800	Great Ormond Street Hospital for Children NHS Foundation Trust\|Newcastle-upon-Tyne Hospitals NHS Trust	Allogeneic Haematopoietic Stem Cell Transplantation	March 2014
NCT02349906	medac GmbH\|Celerion\|Venn Life Sciences\|Syneos Health	Primary Immunodeficiencies\|Inborn Errors of Metabolism\|Haemoglobinopathies\|Bone Marrow Failure Syndromes	April 2015	Phase 2
NCT00129155	Hospices Civils de Lyon	Hematological Malignancies\|Allogeneic Transplantation	February 2005	Phase 2
NCT00168870	Charite University, Berlin, Germany	Ocular Melanoma	February 2003	Phase 2
NCT00987636	University Hospital Muenster	Ewing´s Sarcoma	October 1, 2009	Phase 3
NCT01772953	Center for International Blood and Marrow Transplant Research\|National Marrow Donor Program\|Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT)\|Pediatric Blood and Marrow Transplant Consortium\|St. Baldrick´s Foundation\|medac GmbH	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	September 2013	Phase 2
NCT02333058	medac GmbH\|Celerion\|Syneos Health	Acute Lymphoblastic Leukaemias (ALL)\|Acute Myeloid Leukaemias (AML)\|Myelodysplastic Syndromes (MDS)\|Juvenile Myelomonocytic Leukaemias (JMML)	November 21, 2014	Phase 2
NCT00253513	OHSU Knight Cancer Institute\|medac GmbH\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	June 2005	Phase 1\|Phase 2
NCT00598624	IRCCS San Raffaele	Leukemia\|Chronic Myeloid Leukemia\|Myelodysplastic Syndrome\|Diffuse Large Cell Lymphoma\|Hodgkin Lymphoma\|Chronic Lymphocytic Leukemia\|Multiple Myeloma	September 2005	Phase 2
NCT00822393	medac GmbH	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	November 24, 2008	Phase 3
NCT04195633	Fred Hutchinson Cancer Center\|medac GmbH	Acute Leukemia\|Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia\|Adult Diffuse Large Cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Burkitt Lymphoma\|Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Chronic Myelomonocytic Leukemia\|Hodgkin Lymphoma\|Lymphoblastic Lymphoma\|Lymphoplasmacytic Lymphoma\|Mantle Cell Lymphoma\|Mixed Phenotype Acute Leukemia\|Myelodysplastic Syndrome\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia\|Refractory Follicular Lymphoma\|Refractory Marginal Zone Lymphoma\|Refractory Small Lymphocytic Lymphoma	January 25, 2021	Phase 2
NCT01894477	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)\|National Heart, Lung, and Blood Institute (NHLBI)	Acute Myeloid Leukemia in Remission\|Chronic Myelomonocytic Leukemia\|Minimal Residual Disease\|Myelodysplastic Syndrome\|Myelodysplastic+Myeloproliferative Neoplasm\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable	November 2013	Phase 2
NCT01810926	Franco Locatelli\|University of Milano Bicocca\|medac GmbH\|Fresenius AG\|Bambino Gesù Hospital and Research Institute	Graft Versus Host Disease	September 2011	Phase 2
NCT03961919	Ciceri Fabio\|IRCCS San Raffaele	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Transplant-Related Hematologic Malignancy	February 10, 2009	Phase 2
NCT01010243	University of Regensburg\|ClinAssess GmbH	Multiple Myeloma	October 2009	Phase 1\|Phase 2
NCT02852083	University Hospital Regensburg\|The Anticancer Fund	Squamous Cell Lung Cancer\|Non-Squamous Cell Lung Cancer\|Non-Small Cell Lung Cancer	January 2016	Phase 2
NCT01062490	medac GmbH	Myelodysplastic Syndrome	November 2004	Phase 2
NCT05534620	medac GmbH\|Synteract, Inc.	Acute Myeloid Leukaemia (AML)\|Myelodysplastic Syndrome (MDS)\|Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	October 2022	Phase 1
NCT00860574	Fred Hutchinson Cancer Center\|National Heart, Lung, and Blood Institute (NHLBI)\|National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Lymphoblastic Leukemia in Remission\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Blastic Phase Chronic Myelogenous Leukemia\|Childhood Acute Lymphoblastic Leukemia in Remission\|Childhood Acute Myeloid Leukemia in Remission\|Childhood Chronic Myelogenous Leukemia\|Childhood Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Childhood Acute Lymphoblastic Leukemia	February 2009	Phase 2
NCT01063647	medac GmbH	Hematological Malignancies	November 2001	Phase 1\|Phase 2
NCT03980769	Fred Hutchinson Cancer Center	Non-Neoplastic Hematologic and Lymphocytic Disorder	May 5, 2021	Phase 2
NCT04400045	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Nijmegen Breakage Syndrome	May 22, 2020	Phase 2
NCT01063660	medac GmbH	Acute Myeloid Leukaemia	March 2004	Phase 2
NCT00796068	Fred Hutchinson Cancer Center	Acute Biphenotypic Leukemia\|Acute Lymphoblastic Leukemia in Remission\|Acute Myeloid Leukemia in Remission\|Blasts Under 5 Percent of Bone Marrow Nucleated Cells\|Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Myelodysplastic Syndrome	October 29, 2008	Phase 2
NCT04994808	Fred Hutchinson Cancer Center\|Medexus Pharma, Inc.	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome	November 30, 2022	Phase 2
NCT00491634	Dr. Avichai Shimoni MD\|Sheba Medical Center	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	June 2007	Phase 2
NCT00919503	Fred Hutchinson Cancer Center\|medac GmbH\|National Cancer Institute (NCI)\|National Heart, Lung, and Blood Institute (NHLBI)	Non-Neoplastic Hematologic and Lymphocytic Disorder	July 31, 2009	Phase 2
NCT01949129	St. Anna Kinderkrebsforschung\|ALL SCTped Forum\|European Society for Blood and Marrow Transplantation\|ALL-BFM Study Group\|Assistance Publique - Hôpitaux de Paris\|Dutch Childhood Oncology Group\|Swiss Pediatric Oncology Group\|Australian & New Zealand Children´s Haematology+Oncology Group	Acute Lymphoblastic Leukaemia	April 2013	Phase 2\|Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 359.32 mM )

H ₂ O : 50 mg/mL ( 179.66 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5932 mL	17.9662 mL	35.9324 mL
5 mM	0.7186 mL	3.5932 mL	7.1865 mL
10 mM	0.3593 mL	1.7966 mL	3.5932 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 16.67 mg/mL (59.90 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, (2S,3S)-

1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, [S-(R*,R*)]-

Threitol, 1,4-dimethanesulfonate, (2S,3S)-

(2S,3S)-Threitol 1,4-bismethanesulfonate

Threosulphan

Treosulfan

Tresulfan

Treosulphan

NSC 39069

L-Threitol 1,4-bis(methanesulfonate)

Ovastat

Trecondi